Mercer Capital's Value Focus: Medical Device Industry | Q1 2018 | Featured Article: Five Trends to Watch in the Medical Device Industry

VALUE FOCUS
Medical Device Industry
First Quarter 2018
BUSINESS VALUATION &
FINANCIAL ADVISORY SERVICES
www.mercercapital.com
Executive Summary 1
Stock Market Performance 2
Venture Capital Funding Exit Activity 8
Medical Device IPOs 10
Select Operating Metrics 13
Transactions 14
Five Trends to Watch in the
Medical Device Industry 20
Public Medical Device Companies 33
About Mercer Capital 39

© 2018 Mercer Capital // www.mercercapital.com 1
Mercer Capital’s Value Focus: Medical Device Industry First Quarter 2018
This edition of the medical device quarterly update includes a broad outlook that enumerates long and short-term
industry trends. In particular, we are interested observers of how technological changes could spur innovation within
the industry along three dimensions: i) traditional products (hardware), ii) data and communications (software), and iii)
business model changes. As in other years, the combination of structural trends and shorter-term developments could
potentially result in a very active 2018 for mergers, acquisitions, and divestitures.
The transactions section reviews a few notable deals from 2017. Observed themes undergirding these transactions
will also be useful in framing and thinking about likely activity in 2018 and beyond. Also included in the section is a
summary of purchase price allocations for a selection of transactions as reported by acquirers.
As usual, this update also includes a review of public company returns by subsector, trends in implied valuation multiples,
venture capital activity, and select operating metrics.
Mercer Capital has broad experience in providing valuation services to medical device start-ups, larger public and
private companies, and private equity and venture capital funds involved in the sector. Please contact us to discuss
how we can be of help.
Executive
Summary

The medical device sector outpaced broader markets over the twelve months ended 4Q17. In aggregate, total
shareholder returns (price appreciation and dividends) for medical device companies were 29.1% compared to 21.3%
for the SP 500 during the period.
The cardiovascular subsector gained the most over the year ended 4Q17, with total returns north of 40%. IVD and large
diversified companies (included in Mercer Capital groups) gained 28.0% and 26.5%, respectively, over the same period.
Orthopedic-focused medical device companies returned 16.2% over the twelve months, the only subsector that trailed
the SP 500 index in 2017.
IVD companies returned nearly 10% in 4Q17 alone. Orasure Technologies realized the largest gains among group
constituents over 2017 (113.3%) despite falling nearly 20% in 4Q17. Bruker (61.7%), Haemonetics (45.3%), and Bio
Rad Labs (30.3%) each also realized large gains. GenMark Diagnostics fell nearly 70% over the year, with the biggest
decline occurring after a sizable revenue miss in 3Q17. Select subsector notes include:
»» Bruker acquired MERLIN Diagnostika GmbH in 3Q17, expanding Bruker´s microbiology business.
The company also introduced two new CE Mark registered diagnostic products in 4Q17.
»» Hologic received 510(k) clearance in 4Q17 from the FDA for its Quantra 2.2 Breast Density
Assessment Software, which enables clinicians to provide women with breast density assessments
during breast cancer screenings. The FDA also granted 510(k) clearance for the company’s Panther
Fusion AdV/hMPV/RV assay, a multiplex test that detects adenovirus, human metapneumovirus, and
rhinovirus.
Cardiovascular companies returned a collective 42.1% from 4Q16 to 4Q17, the largest among the analyzed sub-sectors.
Abiomed (65.0%), Integer (51.0%), Teleflex (55.0%), and ICU Medical (48.9%) all had large returns in 2017. Select
subsector notes include:
»» Becton Dickinson completed the acquisition of C.R. Bard in late 4Q17. (This deal is discussed in
more detail in a subsequent section.)
Stock Market
Performance

»» Cryolife returned a negative 1.0% over 2017 following a near 16% decline in 4Q17. The stock fell over
14% after the company’s 3Q17 performance announcement, which coincided with the company’s
announced takeover of JOTEC GmbH, a developer of surgical devices and endovascular implants.
»» Abiomed announced in 3Q17 that it had received FDA premarket approval (PMA) for the Impella
RP heart pump that provides temporary right ventricular support, the only FDA-approved device of its
kind on the market according to the company.
The orthopedics segment lagged the broader markets on a total return basis over 2017. Exactech (81.5%) realized the
largest total returns, driven by an impressive 4Q17 (50.1%) gain following news the company would be taken private
by TPG Capital. (This deal is discussed in more detail in a subsequent section.) Globus Medical (65.5%) and Orthofix
(52.6%) also realized large 2017 returns. Other sub-sectors notes include:
»» Zimmer Biomet Holdings appointed Bryan Hanson as CEO in 4Q17. Zimmer’s stock rose 6% on the
announcement. The company returned 17.5% over the year despite a tumultuous 2Q/3Q17.
»» According to a Globus Medical press release, results from a 380-subject IDE study demonstrated the
superiority of the company’s SECURE-C Cervical Artificial Disk over the current standard of care for the
treatment of cervical disc disease, anterior cervical discectomy, and fusion (ACDF).
»» Wright Medical acquired Imascap in 4Q17, which develops software solutions used for preoperative
planning of shoulder replacement surgery. Imascap’s Glenosys technology is the preoperative software
behind Wright’s current preoperative planning offering.
»» Smith Nephew acquired privately held Rotation Medical in 4Q17, which specializes in rotator cuff
disease treatment. Smith Nephew also launched MolecuLight i:X during 4Q17, a handheld imaging
device that instantly measures wound surface area and visualizes the presence and distribution of
harmful bacteria in wounds.
Stock Market
Performance

The group of large, diversified companies returned 26.5% over 2017 and 7.6% in 4Q17, outpacing broader markets on
both an annual and quarterly basis. Total returns for group constituents ranged from 14.2% to 52.4%. Subsector notes
include:
»» Stock prices of of heart stents sellers – Abbott, Boston Scientific, and Medtronic – ticked slightly lower
upon the publication of findings from a study that questioned whether the devices alleviate chest
pain.
»» Stryker agreed to acquire Entellus Medical, which developed products for ear, nose, and throat
(ENT) procedures. (This deal is discussed in more detail in a subsequent section.)
Stock Market
Performance

Sector Stock Prices
Industry Stock Prices
-10%
0%
10%
20%
30%
40%
50%
60%
Dec 29, 2016 Mar 29, 2017 Jun 29, 2017 Sep 29, 2017 Dec 29, 2017
SP 500 Large, Diversified IVD and Life Sciences Cardiovascular Orthopedics and Spine
-5%
0%
5%
10%
15%
20%
25%
30%
35%
Dec 29, 2016 Apr 29, 2017 Aug 29, 2017 Dec 29, 2017
Total Med Device SP
Individual sub-sectors performance represented by market capitalization weighted indexes for each group. IVD group presented exclusive of ILMN
Source: Bloomberg, Mercer Capital analysis
Represents market capitalization weighted index of all Med Device companies followed by Mercer Capital.
Source: Bloomberg, Mercer Capital analysis

4.85x
3.65x
3.98x
4.48x 4.33x 4.09x
4.43x 4.64x
4.23x
4.21x
0.00x
1.00x
2.00x
3.00x
4.00x
5.00x
6.00x
7.00x
8.00x
9.00x
4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17
75% Quartile Median 25% Quartile
Large Diversified
EV / Trailing LTM Revenue
Cardiovascular
IVD and Life Sciences
Orthopedics
6.12x
4.26x
3.46x
0.00x
1.00x
2.00x
3.00x
4.00x
5.00x
6.00x
7.00x
8.00x
9.00x
2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17
4.14x
3.44x
2.22x
0.00x
1.00x
2.00x
3.00x
4.00x
5.00x
6.00x
7.00x
8.00x
9.00x
2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17
5.10x
4.43x
4.17x
0.00x
1.00x
2.00x
3.00x
4.00x
5.00x
6.00x
7.00x
8.00x
9.00x
2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17
Median Revenue multiples from each MCM group. Data source: Bloomberg
Revenue Multiples
6.74x
3.44x
3.01x
0.00x
1.00x
2.00x
3.00x
4.00x
5.00x
6.00x
7.00x
8.00x
9.00x
2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17

4.85x
3.65x
3.98x
4.48x 4.33x 4.09x
4.43x 4.64x
4.23x
4.21x
0.00x
1.00x
2.00x
3.00x
4.00x
5.00x
6.00x
7.00x
8.00x
9.00x
4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17
75% Quartile Median 25% Quartile
Large Diversified
EV / Trailing LTM EBITDA
Cardiovascular
IVD and Life Sciences
Orthopedics
36.5x
24.2x
21.5x
0.0x
5.0x
10.0x
15.0x
20.0x
25.0x
30.0x
35.0x
40.0x
2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17
18.0x
15.2x
15.0x
0.0x
5.0x
10.0x
15.0x
20.0x
25.0x
30.0x
35.0x
40.0x
2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17
18.8x
16.3x
15.3x
0.0x
5.0x
10.0x
15.0x
20.0x
25.0x
30.0x
35.0x
40.0x
2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17
Median EBITDA multiples from each MCM group. Data source: Bloomberg
EBITDA Multiples
33.3x
24.2x
16.2x
0.0x
5.0x
10.0x
15.0x
20.0x
25.0x
30.0x
35.0x
40.0x
2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17

While venture capital funding for healthcare rose over 20% from 3Q17 to 4Q17, funding for medical devices fell to their
lowest level in 2017. VC funding for medical device and equipment companies fell nearly 40% to $505 million in 4Q17.
Device deal volume was relatively constant at 56 in 4Q17 (compared to 55 in 3Q17), but the average deal value fell to
$9.0 million (the lowest level observed since 1Q14). Medical device companies’ share of VC funding accounted for 2.7%
of all VC investments during 4Q17, the lowest level observed since 2002.
A total of $1.3 billion was invested into Biotechnology related industries in 4Q17, an increase of 11.7% from the prior
quarter, and total healthcare VC funding rose to nearly $4.0 billion. Overall, 2017 represented a record high level of
funding directed towards healthcare at $14.4 billion, a 25.2% increase over 2016. Average deal value increased to
$21.8 million, also a record high, in 4Q17. The seven largest healthcare deals in the quarter were in biotechnology, drug
development, or disease diagnosis, with Ginkgo Bioworks, Precision Medicine, and GRAIL all raising more than $200
million each.
Venture Capital
Funding Exit
Activity
Venture Capital Investments in Medical Devices
Data Source: MoneyTree Report; PwC/NVCA, Thomson Reuters, Mercer Capital analysis
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
$0.0
$0.2
$0.4
$0.6
$0.8
$1.0
$1.2
$1.4
$1.6
Billions
Medical Devices and Equipment Medical Devices and Equipment as a % of Total Investments

Venture Capital
Funding Exit
Activity
VC exit activity, which includes acquisitions, secondary buyouts, and IPOs continues to gradually decline from heightened
levels seen over the last few years. Total VC exit value was $51.0 billion across 769 exits over 2017. Average exit values
have increased, resulting in only marginally lower total exit value compared to 2016 ($52.9 billion) despite a 10% drop in
exit volume. Total exits of 769 were the lowest annual level since 2011. Healthcare, including medical devices, has not
been immune to these trends, seeing exit volume decline over the last several periods. 2017 represented the lowest
exit volume for healthcare since 2010.
U.S. Venture-Backed Exits (#) by Sector
0
50
100
150
200
250
2010 2011 2012 2013 2014 2015 2016 2017
Pharma Biotech HC Services Systems HC Devices Supplies
Source: NVCA Venture Monitor: 4Q 2017, Mercer Capital Analysis

Medical Device
IPOs
Medical device IPOs slowed since their recent
peak in 2014, with 27 recorded medical device
companies filing IPOs over 2017. Estimated
aggregate IPO proceeds of $2.2 billion in
2017 were well below figures observed over
the last several years.
Medical Device IPOs
2017 IPO Summary Statistics
0
10
20
30
40
50
60
70
80
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
2011 2012 2013 2014 2015 2016 2017
#ofIPOs
$MillionsofProceeds
Aggregate Proceeds # IPOs
Source: Capital IQ, Mercer Capital Analysis
Metrics Observations
Return Since IPO
(through Feb. 1, 2018)
Median returns for companies going public in 4Q17 = 22.3%
Median returns for companies that IPOed in 2017 = 32.7%
Range = -55% to 188%
LTM Performance
16 of 27 companies in sample had no trailing 12-month revenue
1 company had positive EBITDA
Projected Revenue Growth
Median projected revenue growth from 2017 to 2018 = 58%
Median projected revenue growth from 2018 to 2019 = 45%
12 companies project no revenue in 2018, 7 project no revenue in 2019
Forward-looking information not available for 5 companies
Summary revenue growth statistics based only on companies for which forward-looking estimates were available.
Returns represent changes in price between IPO date and February 1, 2018 (i.e., are not annualized).

Issuer Offer Date Offer Price
2/1/18
Stock Price
% Return
Since IPO LTM Revenue LTM EBITDA
Implied 17-18
Revenue
Growth %
Implied 18-19
Revenue
Growth %
Cue Biopharma, Inc. 12/27/17 7.50 14.95 99.3% $0.0 ($15.3) nm nm
Denali Therapeutics Inc. 12/7/17 18.00 21.18 17.7% $0.0 ($83.4) nm -13%
Quanterix Corporation 12/6/17 15.00 19.90 32.7% $23.0 ($25.3) 50% 51%
Arsanis, Inc. 11/15/17 10.00 12.70 27.0% $0.0 ($30.0) nm nm
Apellis Pharmaceuticals, Inc. 11/8/17 14.00 16.42 17.3% $0.0 $0.0 nm nm
TissueGene, Inc. 11/5/17 24.19 51.07 111.1% $0.0 $0.0 nm nm
Spero Therapeutics, Inc. 11/1/17 14.00 12.55 -10.4% $1.3 ($36.2) 235% 30%
Allena Pharmaceuticals, Inc. 11/1/17 14.00 8.23 -41.2% $0.0 ($20.3) nm nm
Restoration Robotics, Inc. 10/11/17 7.00 5.07 -27.6% $20.6 ($16.3) 33% 45%
Rhythm Pharmaceuticals, Inc. 10/4/17 17.00 31.05 82.6% $0.0 ($29.6) nm nm
Deciphera Pharmaceuticals, Inc. 9/27/17 17.00 26.83 57.8% $0.0 ($39.0) nm nm
Celcuity Inc. 9/20/17 9.50 16.58 74.5% $0.0 ($4.9) nm nm
Krystal Biotech, Inc. 9/19/17 10.00 9.69 -3.1% $0.0 ($3.9) nm nm
Medical Devices IPOs
2017

Issuer Offer Date Offer Price
2/1/18
Stock Price
% Return
Since IPO LTM Revenue LTM EBITDA
Implied 17-18
Revenue
Growth %
Implied 18-19
Revenue
Growth %
Calyxt, Inc. 7/19/17 8.00 23.01 187.6% $0.4 ($22.9) 1585% 946%
Co-Diagnostics, Inc. 7/12/17 6.00 2.71 -54.8% $0.0 ($3.5) nm nm
Aileron Therapeutics, Inc. 6/28/17 15.00 9.25 -38.3% $0.0 ($20.3) nm nm
Mersana Therapeutics, Inc. 6/27/17 15.00 14.37 -4.2% $26.3 ($23.2) 26% 28%
Imagion Biosystems, Inc. 6/21/17 0.15 0.07 -52.2% $0.0 ($3.7) nm nm
Athenex, Inc. 6/14/17 11.00 14.68 33.5% $28.3 ($115.8) 58% 19%
G1 Therapeutics, Inc. 5/16/17 15.00 23.31 55.4% $0 ($60.9) nm nm
ENDRA Life Sciences Inc. 5/8/17 5.00 3.48 -30.4% $0.9 ($2.6) nm nm
Ovid Therapeutics Inc. 5/4/17 15.00 8.83 -41.1% $0 ($61.5) nm nm
Biohaven Pharmaceutical Holding Company Ltd. 5/3/17 17.00 32.70 92.4% $0 ($102.1) nm 2411%
Tocagen Inc. 4/12/17 10.00 13.39 33.9% $0 ($34.7) 5% 122227%
Visioneering Technologies, Inc. 3/27/17 0.32 0.44 37.7% $0 ($8.9) 670% 253%
BeyondSpring Inc. 3/8/17 20.00 26.64 33.2% $0.0 ($84.9) nm nm
Jounce Therapeutics, Inc. 1/26/17 16.00 23.98 49.9% $78.9 $1.4 60% -38%
Medical Devices IPOs
2017

Median measures for each group. | Data Source: Bloomberg, Mercer Capital Analysis
Gross Margin EBITDA Margin Operating Margin RD / Revenue
Segment Q4 2017 Q3 2017 Q4 2017 Q3 2017 Q4 2017 Q3 2017 Q4 2017 Q3 2017
Large, Diversified 65.7% 66.1% 27.3% 27.4% 14.2% 12.5% 7.4% 7.3%
IVD Life Sciences 52.7% 53.0% 18.5% 17.3% 7.0% 7.6% 9.2% 9.4%
Cardiovascular 69.0% 69.0% 19.2% 19.7% 8.4% 9.6% 8.3% 8.1%
Ortho, Implants Prosthetics 72.7% 72.2% 17.1% 17.4% 7.1% 7.3% 5.8% 5.8%
Other 52.1% 52.0% 5.3% 6.7% -0.7% -0.9% 8.2% 8.2%
All Companies 55.3% 55.0% 18.8% 17.6% 7.1% 7.8% 7.5% 7.6%
Historical Rev
Growth LT Fwd Op Earn Grwth Debt / EV Debt / EBITDA
Segment Quarterly Annual Q4 2017 Q3 2017 Q4 2017 Q3 2017 Q4 2017 Q3 2017
Large, Diversified 2.5% 1.4% 9.5% 10.2% 14.2% 12.8% 2.5 2.5
IVD Life Sciences 1.9% 1.9% 13.2% 14.2% 7.2% 7.1% 1.5 1.6
Cardiovascular 2.5% 2.5% 15.0% 15.0% 7.0% 3.3% 1.6 0.8
Ortho, Implants Prosthetics 0.8% 1.3% 12.9% 10.9% 17.5% 19.4% 2.8 3.2
Other 2.3% 1.6% 12.5% 11.3% 4.5% 3.6% 0.4 0.0
All Companies 1.9% 1.5% 13.0% 12.1% 8.8% 7.9% 1.6 1.5
Select
Operating
Metrics

Medical Devices Select Transactions Summary
($Millions)
Implied Enterprise Value
Acquirer Target
Announce
Date
Closed
Date
Implied
EV EBIT EBITDA Revenue Sector
Roche Holdings, Inc. Ignyta, Inc. 12/21/17 2/7/18 1,823.8 NM NM NA Biotechnology
TPG Capital, L.P. Exactech, Inc. 10/22/17 2/14/18 709.6 31.0x 16.5x 2.68x Healthcare Equipment
Stryker Corporation Entellus Medical, Inc. 12/7/17 NA 663.9 NM NM 7.70x Healthcare Equipment
JSR Corporation Crown Bioscience International 12/11/17 NA 345.5 61.7x 34.9x 4.79x
Life Sciences Tools and
Services
Boston Scientific Corporation Apama Medical, Inc. 10/2/17 10/10/17 300.0 NA NA NA Healthcare Equipment
Ambu A/S invendo medical GmbH 10/25/17 10/25/17 265.7 NA NA NA Healthcare Equipment
CryoLife, Inc. JOTEC GmbH 10/10/17 12/1/17 253.6 NA NA 4.97x Healthcare Supplies
Edwards Lifesciences Corporation Harpoon Medical, Inc. 12/1/17 12/1/17 250.0 NA NA NA Healthcare Equipment
Guangzhou Kunlun Investment Co., Ltd. Guangzhou Xiehe Precision Medical Co., Ltd. 12/8/17 1/3/18 244.7 NA NA NA Biotechnology
Smith Nephew plc Rotation Medical Inc. 10/23/17 12/6/17 210.0 NA NA NA Healthcare Equipment
Zhongyuan Union Cell Gene Engineering
Corp., Ltd
Shanghai Aoyuan Medical Supplies Co., Ltd. 11/8/17 NA 180.8 109.8x NA 2.62x Biotechnology
Shanghai Runda Medical Technology Co., Ltd.;
et al
ReLIA Biotechnologies (Shenzhen), Inc. 10/13/17 NA 179.2 NA NA 9.46x Healthcare Equipment
Lupin Inc. Symbiomix Therapeutics, LLC 10/11/17 10/11/17 150.0 NA NA NA Biotechnology
Mitsubishi Tanabe Pharma Corporation Stelic Institute Co., Inc. 11/1/17 NA 104.4 NA NA NA Biotechnology
Over $10mm Transaction | Data Source: Bloomberg and Capital IQ

Medical Devices Select Transactions Summary
($Millions)
Implied Enterprise Value
Acquirer Target
Announce
Date
Closed
Date
Implied
EV EBIT EBITDA Revenue Sector
Livzon Biotechnology (Hong Kong) Co., Ltd. Livzon Mabpharm, Inc. 12/21/17 NA 91.1 NA NA NA Biotechnology
BTG plc Roxwood Medical, Inc. 10/5/17 10/5/17 80.0 NA NA NA Healthcare Equipment
CooperVision, Inc. Paragon Vision Sciences, Inc. 12/1/17 12/1/17 80.0 NA NA 5.33x Healthcare Supplies
Wuhu Jiujiu Equity Investment Partnership
Enterprise (LP)
Bioland Technology (Shenzhen) Ltd. 12/11/17 NA 45.3 NA NA 2.44x Healthcare Equipment
Altus Capital Partners;Altus Capital Partners II, L.P. MGC Diagnostics Corporation 11/25/17 12/27/17 43.8 39.2x 24.4x 1.08x Healthcare Equipment
Ligand Pharmaceuticals Incorporated Crystal Bioscience Inc. 10/4/17 10/6/17 35.5 NA NA NA Biotechnology
OneLife Technologies Corp. Yinuo Technologies LTD 12/22/17 NA 35.0 NA NA NA Healthcare Equipment
Neovia S.A.S. Epicore BioNetworks Inc. 10/13/17 12/18/17 24.2 8.9x 8.3x 2.04x Biotechnology
Summit Therapeutics plc Discuva Limited 12/23/17 12/23/17 13.2 NA NA NA
Life Sciences Tools and
Services
ImmunoPrecise Antibodies Ltd. Crossbeta Biosciences B.V. 12/22/17 NA 10.1 NA NA NA Biotechnology
Over $10mm Transaction | Data Source: Bloomberg and Capital IQ

Transactions
Summary
A number of large transactions involving medical device companies in 2017 were generally motivated by the desire
to pursue higher growth, either through product portfolio acquisitions or divestments. For more mature operations,
post-acquisition cash flow growth may be predicated primarily on expected revenue trajectory. However, incremental
opportunities for margin expansion may also be available from transactions of size. Select examples of acquisitions
expected to fill out or expand product portfolios and/or global footprint:
»» Abbott acquired St.Jude Medical (announced April 2016, closed January 2017) in a cash and stock deal
for a total consideration of approximately $23.6 billion, and assumption of $5.9 in debt. The transaction
is expected to make Abbott a leader in high-growth cardiovascular, including atrial fibrillation, structural
heart and heart failure, and neuromodulation markets. Following the transaction, combined annual
revenue for the cardiovascular business is expected to be approximately $8.7 billion (with an aggregate
market opportunity of $30 billion). As part of the transaction, the combined company announced sale
of a part of their vascular business to Terumo for $1.1 billion in October 2016.
»» Hologic acquired Cynosure in March 2017 for a total consideration of approximately $1.7 billion. The
transaction is expected to facilitate the acquirer’s expansion into the medical aesthetics market with
non-invasive and minimally invasive treatment systems that could be marketed to plastic surgeons,
dermatologists and other medical practitioners.
»» Stryker acquired NovadaqTechnologies in September 2017 for a total consideration of approximately
$716 million. Novadaq is developing fluorescence imaging technology that provides surgeons
with visualization of blood flow in vessels and related tissue perfusion in cardiac, cardiovascular,
gastrointestinal, plastic, microsurgical and reconstructive procedures.
»» Abbott acquired Alere (first announced in February 2016, the deal faced some interim difficulties
before final agreement in April 2017, and closed in October 2017) for a purchase price of $4.5 billion for
common shares, $0.7 billion for preferred shares, and assumption of $3.0 billion in debt. The acquisition
is expected to enhance Abbott’s market share in point of care testing and diagnostics by providing
access to new products, channels and geographies.

Transactions
Summary
»» Becton, Dickinson and Company acquired C.R. Bard in a cash and stock transaction in December
2017 for a total consideration of approximately $25.0 billion. The transaction is expected to expand the
acquirer’s existing product offering and shore up the innovation pipeline for opportunities in fast-
growing clinical areas. Revenue and cost synergies are also expected.
»» Stryker announced the acquisition of Entellus Medical in December 2017 for a total consideration of
approximately $662 million. Entellus is a high-growth global medical technology company with products
designed for the minimally invasive treatment of various ear, nose and throat (ENT) diseases. The
acquired products are complementary to Stryker’s existing portfolio.
Companies also looked to divest certain lines of businesses with the intent to prop up faster growth rates for the retained
product portfolio. Presumably, acquirers of these businesses or segments foresee benefits in the form of cost synergies
or other strategic elements (diversification, geographic expansion, and others). Select examples:
»» Abbott sold its vision care business, Abbott Medical Optics (AMO), to Johnson and Johnson for
$4.3 billion in cash in February 2017. The acquirer expects to achieve unspecified synergies as a result
of the transaction.
»» Johnson and Johnson divested its Codman Neurosurgery business to Integra Lifesciences Holdings
Corp in October 2017 for an aggregate purchase price of $1.0 billion. The acquirer expects the
acquisition will expand its portfolio of neurosurgery products and increase international footprint.
A somewhat different type of transaction – a vertical integration – represented a strategic move to make changes
in the business model. In August 2017, Fresenius Medical Care announced the acquisition of NxStage Medical for
approximately $2.0 billion. Fresenius primarily is a service provider that operates a network of 3,690 dialysis clinics.
NxStage develops and markets products for the treatment of end-stage renal disease and acute kidney failure. The
acquisition is expected to allow Fresenius to leverage its expertise in providing dialysis services to offer care and
services in home-care settings, as well, with its own products. Cost synergies are expected to be on the order of
$80 million to $100 million annually. It remains to be seen if a portion of the cost savings will be passed on to
customers in order to support the company’s competitive position.

Transactions
Summary
Finally, a transaction that did not fit the more common acquisition/divestment theme involved the take-private of
Exactech by TPG Capital. The transaction, first announced in October 2017, was completed in February 2018 for a total
consideration of $737 million. The final purchase price represented an almost 18% premium to the initial offer after an
alleged unsolicited interest from another financial buyer. The deal is expected to afford Exactech management
space to invest in long-term growth.
The next page presents a summary of purchase price allocations for select transactions reported by the acquirers.
While a healthy allocation to goodwill for young companies is generally not surprising (in part, owing to a relative
dearth of identifiable intangible assets), goodwill balances resulting from the acquisitions of some of the more mature
companies or businesses is perhaps suggestive of the attractive pricing available in the industry during 2017.

Abbott Hologic Stryker Abbott BDX JNJ Integra
STJ Cynosure Novadaq Alere C.R. Bard AMO Codman
Purchase Price Allocations ($millions)
Tangible assets, net $15,500 $309 $92 $900 $2,614 $300 $145
Customer relationships na $35 $18 na $1,122 na $0
Trade name na 74 1 na 0 na 163
Developed technology na 736 133 na 11,738 na 380
IPRD na 107 0 na 0 na 0
Other na 42 na 0 na 0
Identifiable intangible assets 3,000 994 152 3,500 12,860 2,300 543
Goodwill 13,100 684 521 4,100 15,054 1,700 346
Other 0 12 9 0 490 0 0
Assets $31,600 $1,999 $774 $8,500 $31,018 $4,300 $1,034
Net debt ($5,300) $0 $0 ($2,600) ($1,692) na $0
Non-interest bearing liabilities and other (2,700) (341) (58) (700) (4,309) na (20)
Preferred stock na na na (700) na na 0
Liabilities acquired ($8,000) ($341) ($58) ($4,000) ($6,001) $0 ($20)
Total consideration $23,600 $1,658 $716 $4,500 $25,017 $4,300 $1,014
Relative Allocation – % of Total Intangible Assets
Customer relationships nm 2% 3% nm 4% nm 0%
Trade name nm 4% 0% nm 0% nm 18%
Developed technology nm 44% 20% nm 42% nm 43%
IPRD nm 6% 0% nm 0% nm 0%
Other nm 3% 0% nm 0% nm 0%
Identifiable intangible assets 19% 59% 23% 46% 46% 58% 61%
Goodwill 81% 41% 77% 54% 54% 43% 39%
Total intangible assets 100% 100% 100% 100% 100% 100% 100%
Sources: 2017 10-K filed by ABT. Final allocation for St. Jude, and preliminary allocation for Alere shown. 10-Q for period ended December 2017 filed by HOLX. Preliminary allocation for Cynosure shown. 2017 10-K
filed by SYK. Preliminary allocation for Novadaq shown. 10-Q for period ended December 2017 filed by BDX. Preliminary allocation for C.R. Bard shown. 2017 10-K filed by JNJ. Final allocation for AMO shown. 2017
10-K filed by IART. Preliminary allocation for Codman Neuro shown.

Five Trends
to Watch
The medical device manufacturing industry produces equipment designed to diagnose and treat patients
within global healthcare systems. Medical devices range from simple tongue depressors and bandages, to
complex programmable pacemakers and sophisticated imaging systems. Major product categories include
surgical implants and instruments, medical supplies, electro-medical equipment, in-vitro diagnostic equipment
and reagents, irradiation apparatuses, and dental goods.
The following outlines five structural factors and trends that influence demand and supply of medical devices
and related procedures.
Demographics
The aging population, driven by declining fertility rates and increasing life expectancy, represents a major
demand driver for medical devices. The U.S. elderly population (persons aged 65 and above) totaled 49 million
in 2016 (15% of the population). The U.S. Census Bureau estimates that the elderly will roughly double by
2060 to 95 million, representing 23% of the total population.
in the Medical
Device Industry
Sujan Rajbhandary, CFA
sujanr@mercercapital.com
Atticus Frank
franka@mercercapital.com
1
U.S. Population Distribution by Age Group
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
2060
2016
1960
0 - 17 18 - 44 45 - 64 65 - 84 85 and Over
Source: U.S. Census Bureau

0 - 17
23%
18 - 44
36%
45 - 64
26%
65 - 84
13%
85 and
Over
2%
0 - 17
12%
18 - 44
21%
45 - 64
33%
65 - 84
26%
85 and
Over
8%
U.S. Population
Distribution by Age
U.S. Healthcare Cost
Distribution by Age
Source: U.S. Census Bureau, Centers for Medicare and Medicaid Services, Office of the Actuary,
National Health Statistics Group
The elderly account for nearly one third of total healthcare consumption. Personal healthcare spending for the
population segment was $19,000 per person in 2012, five times the spending per child ($3,600) and almost
triple the spending per working-age person ($6,600).
According to United Nations projections, the global elderly population will rise from approximately 610 million
(8.3% of world population) in 2015 to 1.8 billion (17.8% of world population) in 2060. Europe’s elderly are
projected to reach nearly 29% of the population by 2060, making it the world’s oldest region. While Latin
America and Asia are currently relatively young, these regions are expected to undergo drastic transformations
over the next several decades, with the elderly population expected to expand from approximately 8% in 2015
to more than 21% of the total population by 2060.

0%
5%
10%
15%
20%
25%
30%
35%
Africa Asia Europe Lat Am Caribbean
North America Oceania World
Source: United Nations, Department of Economic and Social Affairs, Population Division (2017). World
Population Prospects: The 2017 Revision, custom data acquired via website.
2
World Population 65 and Over (% of Total)
Healthcare Spending and the Legislative Landscape in the U.S.
Demographic shifts underlie the expected growth in total U.S. healthcare expenditure from $3.3 trillion in
2016 to $5.7 trillion in 2026, an average annual growth rate of 5.5%. This compares to the 7.3% rate observed
from 1990 through 2007 and 4.2% between 2008 and 2016. Projected growth in annual spending for
Medicare (7.4%) and Medicaid (5.8%) is expected to contribute substantially to the increase in national health
expenditure over the coming decade. Healthcare spending as a percentage of GDP is expected to expand
from 18% in 2016 to nearly 20% by 2026.
Since inception, Medicare has accounted for an increasing proportion of total U.S. healthcare expenditures.
Medicare currently provides healthcare benefits for an estimated 57 million elderly and disabled people,
constituting approximately 15% of the federal budget in 2016. Medicare represents the largest portion of
total healthcare costs, constituting 20% of total health spending in 2015. Medicare also accounts for 26% of
hospital spending, 29% of retail prescription drugs sales, and 23% of physician services.

U.S. Healthcare Consumption Payor Mix and as % of GDP
Average Spending Growth Rates, Medicare and Private Health Insurance
0%
5%
10%
15%
20%
25%
0%
20%
40%
60%
80%
100%
1960 1990 2016 2026
HealthExpenditures
asa%ofGDP
PayorMix
Private Health Insurance Medicare / Medicaid
Out-of-Pocket Other
Health Expenditures as a % of GDP
Source: Centers for Medicare Medicaid Services, Office of the Actuary
$24.7 B $674.2 B $3.2 T $5.6 T
Total
Expenditure
5.1%
5.8%
4.5%
4.9%
0%
1%
2%
3%
4%
5%
6%
7%
Medicare Per Capita Spending Private Health Insurance Per Capita Spending
CAGR 2000 - 2016 CAGR 2016 - 2026
Source: Kaiser Family Foundation

Owing to the growing influence of Medicare in aggregate healthcare consumption, legislative developments
can have a potentially outsized effect on the demand and pricing for medical products and services. Net
mandatory benefit outlays (gross outlays less offsetting receipts) to Medicare totaled $588 billion in 2016, and
are expected to reach $1.1 trillion by 2026.
The Patient Protection and Affordable Care Act (“ACA”) of 2010 incorporated changes that are expected to
constrain annual growth in Medicare spending over the next several decades, including reductions in Medicare
payments to plans and providers, increased revenues, and new delivery system reforms that aim to improve
efficiency and quality of patient care and reduce costs. On a per person basis, Medicare spending is projected
to grow at 4.5% annually between 2016 and 2026, compared to 5.1% average annualized growth realized
between 2000 and 2016.
As part ofACA legislation, a 2.3% excise tax was imposed on certain medical devices for sales by manufacturers,
producers, or importers. The tax became effective on December 31, 2012 but met resistance from industry
participants and policy makers. In late 2015, Congress passed legislation promulgating a two-year moratorium
on the tax beginning January 2016. In January 2018, the moratorium suspending the medical device excise
tax was extended through 2019.

Third-Party Coverage and Reimbursement
The primary customers of medical device companies are physicians (and/or product approval committees
at their hospitals), who select the appropriate equipment for consumers (patients). In most developed
economies, the consumers themselves are one (or more) step removed from interactions with manufacturers,
and therefore pricing of medical devices. Device manufacturers ultimately receive payments from insurers,
who usually reimburse healthcare providers for routine procedures (rather than for specific components like the
devices used). Accordingly, medical device purchasing decisions tend to be largely disconnected from price.
Third-party payors (both private and government programs) are keen to reevaluate their payment policies to
constrain rising healthcare costs. Several elements of the ACA are expected to limit reimbursement growth for
hospitals, which form the largest market for medical devices. Lower reimbursement growth will likely persuade
hospitals to scrutinize medical purchases by adopting i) higher standards to evaluate the benefits of new
procedures and devices, and ii) a more disciplined price bargaining stance.
Consumers
Patients
Investors
Government
VC (incl. CVC)
Physicians
Customers
Physicians /
Surgeons
Hospitals
Researchers
Universities
Labs
Physicians
Device
Manufacturers
Regulators
FDA
Government
Payers
Government
insurers
Private insurers
3

The transition of the healthcare delivery paradigm from fee-for-service (FFS) to value models is expected to
lead to fewer hospital admissions and procedures, given the focus on cost-cutting and efficiency. In 2015, the
Department of Health and Human Services (HHS) announced goals to have 85% and 90% of all Medicare
payments tied to quality or value by 2016 and 2018, respectively, and 30% and 50% of total Medicare payments
tied to alternative payment models (APM) by the end of 2016 and 2018, respectively. A report issued by the
Health Care Payment Learning Action Network (LAN), a public-private partnership launched in March 2015
by HHS, found that 29% of payments were tied to APMs, a 6% increase from 2015 to 2016.
While the shift toward value-based care is continuing, the pace could slow under the new administration. In
November 2017, the CMS partially canceled bundled payment programs for certain joint replacement and
cardiac rehabilitation procedures. However, indications are that the CMS supports value-based care and
wants pilot programs to accelerate. Ultimately, lower reimbursement rates and reduced procedure volume will
likely limit pricing gains for medical devices and equipment.
The medical device industry faces similar reimbursement issues globally, as the EU and other jurisdictions
face increasing healthcare costs, as well. A number of countries have instituted price ceilings on certain
medical procedures, which could deflate the reimbursement rates of third-party payors, forcing down product
prices. Industry participants are required to report manufacturing costs and medical device reimbursement
rates are set potentially below those figures in certain major markets like Germany, France, Japan, Taiwan,
Korea, China and Brazil. Whether third-party payors consider certain devices medically reasonable or
necessary for operations presents a hurdle that device makers and manufacturers must overcome in bringing
their devices to market.

Competitive Factors and Regulatory Regime
Historically, much of the growth for medical technology companies has been predicated on continual product
innovations that make devices easier for doctors to use and improve health outcomes for the patients.
Successful product development usually requires significant RD outlays and a measure of luck. However,
viable new devices can elevate average selling prices, market penetration, and market share.
Government regulations curb competition in two ways to foster an environment where firms may realize an
acceptable level of returns on their RD investments. First, firms that are first to the market with a new product
can benefit from patents and intellectual property protection giving them a competitive advantage for a finite
period. Second, regulations govern medical device design and development, preclinical and clinical testing,
premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and
promotions, sales and distribution, export and import, and post market surveillance.
Regulatory Regime in the U.S.
In the U.S., the FDA generally oversees the implementation of the second set of regulations. Some relatively
simple devices deemed to pose low risk are exempt from the FDA’s clearance requirement and can be marketed
in the U.S. without prior authorization. For the remaining devices, commercial distribution requires marketing
authorization from the FDA, which comes in primarily two flavors.
New Device
Clearance or
Approval
to
Market
Device
Class II
510(k)
FDA Determines
Substantial Equivalence
de novo
510(k)
PMA
Clinical Data
Satisfies FDA
Class I
Class III
Low Risk
Predicate
Device
No Predicate
Device
Moderate Risk
High Risk
4

»» The premarket notification (“510(k) clearance”) process requires the manufacturer to
demonstrate that a device is “substantially equivalent” to an existing device that is legally
marketed in the U.S. The 510(k) clearance process may occasionally require clinical data, and
generally takes between 90 days and one year for completion.
»» The premarket approval (“PMA”) process is more stringent, time-consuming, and expensive.
A PMA application must be supported by valid scientific evidence, which typically entails
collection of extensive technical, preclinical, clinical, and manufacturing data. Once the
PMA is submitted and found to be complete, the FDA begins an in-depth review, which is
required by statute to take no longer than 180 days. However, the process typically takes
significantly longer, and may require several years to complete.
Pursuant to the Medical Device User Fee Modernization Act (MDUFA), the FDA collects user fees for the
review of devices for marketing clearance or approval. The current iteration of the Medical Device User Fee
Act (MDUFA IV) came into effect in October 2017. Under MDUFA IV, the FDA is authorized to collect almost
$1 billion in user fees, an increase of more than $320 million over MDUFA III, between 2017 and 2022.
Regulatory Overview Outside the U.S.
The European Union (EU), along with countries such as Japan, Canada, and Australia all operate strict
regulatory regimes similar to that of the FDA, and international consensus is moving towards more stringent
regulations. Stricter regulations for new devices may slow release dates and may negatively affect companies
within the industry.
Medical device manufacturers face a single regulatory body across the EU. In order for a medical
device to be allowed on the market, it must meet the requirements set by the EU Medical Devices Directive.
Devices must receive a Conformité Européenne (CE) Mark certificate before they are allowed to be sold
in that market. This CE marking verifies that a device meets all regulatory requirements, including EU
safety standards. A set of different directives apply to different types of devices, potentially increasing the
complexity and cost of compliance.

Emerging Global Markets
Emerging economies are claiming a growing share of global healthcare consumption, including medical
devices and related procedures, owing to relative economic prosperity, growing medical awareness, and
increasing (and increasingly aging) populations. As global health expenditure continues to increase, sales
to countries outside the U.S. represent a potential avenue for growth for domestic medical device companies.
According to the World Bank, all regions (except Sub-Saharan Africa) have seen an increase in healthcare
spending as a percentage of total output over the last two decades.
Global medical devices sales are estimated to increase 6.4% annually from 2016 to 2020, reaching nearly
$440 billion according to the International Trade Administration.While the Americas are projected to remain the
world’s largest medical device market, the Asia/Pacific and Western Europe markets are expected to expand
at a quicker pace over the next several years.
5
World Health Expenditure as a % of GDP
0%
2%
4%
6%
8%
10%
12%
14%
16%
18%
East Asia
Pacific
Europe
Central Asia
Middle East
North Africa
North
America
(Canada and
US)
South Asia Sub-Saharan
Africa
World
1995 2005 2014
Source: The World Bank

Global Medical Device Market
$167 $177 $187 $198 $209
$69
$73
$78
$83
$89
$15
$16
$17
$18
$19
$10
$11
$12
$13
$13
$80
$85
$93
$101
$106
$0
$50
$100
$150
$200
$250
$300
$350
$400
$450
$500
2016 2017 2018 2019 2020
$BillionsinSales
Americas Asia / Pacific Central / Eastern Middle East / Africa Western Europe
Source: Worldwide Medical Devices Forecast to 2020, 2016 ITA Medical Devices Top Markets Report
Global Device
Sales
6.4% CAGR

Bonus Items for 2018
The following is a (non-ordered) list of items likely relevant for the medical device and medtech industry over
the shorter-term.
Tax Reform
Passage of tax reform legislation in late 2017 appears to have invigorated market participants across many
sectors of the economy. While the full effect of the new legislation will likely play out over the course of the rest
of the year and beyond, the implications for valuation (multiples) are generally expected to be positive. The
effective tax rates for many multinational medical device companies were already below the new corporate
rate. Accordingly, reductions in overall tax burdens for device companies are likely modest. A more immediate
effect materialized in the form of a transition tax on corporate cash parked outside the U.S. (for example,
Johnson and Johnson reported a one-time $13.6 billion charge related to the new tax law). With a lower
tax rate available on deemed repatriation, many corporations will likely have a more direct access to hitherto-
unused overseas funds.
Innovation
Given the structural underpinnings (discussed in earlier sections), continued innovation is probably a low-
risk bet vis-à-vis the medical device industry and is likely to materialize along three dimensions. First, the
traditional product pipeline nursed by the industry over the years is likely to continue turning out iterative and
transformative changes to improve or create new devices (hardware). Second, cost pressures as well as
technological developments outside the industry will likely fuel new data analysis and tele-communication
products and services (software) that augment or complement the traditionally product-only offerings of
device and medtech companies. Finally, business model innovations in response to the changing pricing and
competitive landscape will become increasingly relevant, especially for the more mature devices.

MA
The level of deal activity in the industry observed in 2017 will likely continue in 2018 as consolidation within
certain sub-sectors could provide (a degree of) inoculation against the ravages of competitive forces. Some
potential acquirers will also be buoyed by the unlocking of the cash resources previously trapped overseas.
As in 2017, transaction motivations will likely mirror the three dimensions of innovation as firms pursue
i) acquisition of complementary products, ii) access to newer higher-growth markets or segments, and
iii) ability to address changes in the modes of care delivery that increasingly favor lower acuity settings over
lengthy hospital stays.
Summary
Demographic shifts underlie the long-term market opportunity for medical device manufacturers. While
efforts to control costs on the part of the government insurer in the U.S. may limit future pricing growth for
incumbent products, a growing global market provides domestic device manufacturers with an opportunity
to broaden and diversify their geographic revenue base. Developing new products and procedures is risky
and usually more resource intensive compared to some other growth sectors of the economy. However,
barriers to entry in the form of existing regulations provide a measure of relief from competition, especially
for newly developed products.

Price ∆ Stock Price EV TTM Rev
TTM
EBITDA FWD EBITDA
EV /
Sales
EV /
EBITDA
EV /
FWD EBITDA
Q4 2017 Q3 2017 Q4 2016 Qtrly Annual Q4 2017 Q4 2017 Q4 2017 FY 2018 FY 2019 Q4 2017 Q4 2017 FY 2018 FY 2019
Large, Diversified
Abbott Laboratories $56.80 $52.85 $37.36 7.5% 52.0% $113,026.9 $27,390.0 $7,497.0 $7,710.5 $8,567.4 4.13 15.1 14.7 13.2
Baxter International Inc $64.64 $62.60 $43.88 3.3% 47.3% $35,333.6 $10,561.0 $2,318.0 $2,618.3 $2,914.1 3.35 15.2 13.5 12.1
Becton Dickinson and Co $214.06 $195.28 $163.10 9.6% 31.2% $81,065.9 $12,093.0 $3,277.0 $4,986.1 $5,888.6 6.70 24.7 16.3 13.8
Boston Scientific Corp $24.79 $29.17 $21.63 -15.0% 14.6% $40,062.8 $9,048.0 $2,265.0 $2,837.1 $3,121.2 4.43 17.7 14.1 12.8
Medtronic PLC $80.75 $77.33 $69.67 4.4% 15.9% $124,950.0 $29,710.0 $9,155.0 $9,386.1 $10,098.1 4.21 13.6 13.3 12.4
Johnson Johnson $139.72 $129.22 $112.29 8.1% 24.4% $396,552.3 $76,450.0 $26,616.0 $28,604.4 $30,939.0 5.19 14.9 13.9 12.8
Stryker Corp $154.84 $141.59 $118.35 9.4% 30.8% $62,390.0 $12,444.0 $3,394.3 $3,787.5 $4,100.6 5.01 18.4 16.5 15.2
IVD Life Sciences
Bio-Rad Laboratories Inc $238.67 $222.22 $182.28 7.4% 30.9% $6,820.1 $2,068.2 $264.4 $289.7 $368.0 3.30 25.8 23.5 18.5
Bruker Corp $34.32 $29.72 $21.06 15.5% 63.0% $5,315.3 $1,765.9 $309.4 $354.2 $383.6 3.01 17.2 15.0 13.9
Enzo Biochem Inc $8.15 $10.47 $6.94 -22.2% 17.4% $315.6 $107.8 $1.0 $1.9 $5.1 2.93 324.0 166.1 61.9
GenMark Diagnostics Inc $4.17 $9.63 $12.24 -56.7% -65.9% $171.0 $49.3 ($52.6) ($52.6) ($42.1) 3.47 nm nm nm
Haemonetics Corp $58.08 $44.87 $40.20 29.4% 44.5% $3,086.3 $886.1 $194.4 $212.0 $234.7 3.48 15.9 14.6 13.2
Hologic Inc $42.75 $36.69 $40.12 16.5% 6.6% $14,474.8 $3,058.8 $999.6 $1,056.5 $1,135.6 4.73 14.5 13.7 12.7
Illumina Inc $218.49 $199.20 $128.04 9.7% 70.6% $31,166.5 $2,752.0 $358.0 $962.4 $1,130.6 11.33 87.1 32.4 27.6
Luminex Corp $19.70 $20.27 $19.98 -2.8% -1.4% $740.8 $306.6 $62.3 $59.1 $57.8 2.42 11.9 12.5 12.8
OraSure Technologies Inc $18.86 $22.50 $8.78 -16.2% 114.8% $987.9 $167.1 $34.1 $32.5 $47.4 5.91 28.9 30.4 20.9
Quidel Corp $43.35 $43.86 $21.42 -1.2% 102.4% $1,453.2 $191.6 $41.8 $64.7 $153.4 7.58 34.7 22.5 9.5
Bio-Techne Corp $129.26 $120.31 $101.45 7.4% 27.4% $5,053.3 $563.0 $224.5 $238.1 $269.0 8.98 22.5 21.2 18.8
Trinity Biotech PLC $5.10 $5.61 $6.92 -9.1% -26.3% $155.4 $99.6 nm $12.0 $14.0 1.56 nm 12.9 11.1
Vermillion Inc $1.93 $1.80 $0.95 7.2% 103.2% $109.8 $2.6 ($9.5) NA NA 41.55 nm nm nm
($Millions, except per share figures)
Data Source: Bloomberg
Public Medical Device Companies

Public Medical Device Companies (continued)
TTM
EBITDA FWD EBITDA
EV /
Sales
EV /
EBITDA
EV /
FWD EBITDA
Cardiovascular
ABIOMED Inc $187.41 $168.60 $112.68 11.2% 66.3% $7,935.8 $445.3 $148.4 $169.8 $219.8 17.82 53.5 46.7 36.1
BioTelemetry Inc $29.90 $33.00 $22.35 -9.4% 33.8% $1,154.8 $208.3 $49.2 $64.5 $94.1 5.54 23.5 17.9 12.3
Cardiovascular Systems Inc $23.69 $28.15 $24.21 -15.8% -2.1% $700.4 $204.9 $3.7 $15.0 $21.8 3.42 191.4 46.6 32.1
CryoLife Inc $19.15 $22.70 $19.15 -15.6% 0.0% $705.9 $180.4 $28.2 $28.1 $39.7 3.91 25.0 25.1 17.8
Edwards Lifesciences Corp $112.71 $109.31 $93.70 3.1% 20.3% $23,550.6 $3,435.3 $1,068.6 $1,256.0 $1,396.9 6.86 22.0 18.8 16.9
Integer Holdings Corp $45.30 $51.15 $29.45 -11.4% 53.8% $3,021.0 $1,386.8 $276.4 $281.0 $306.0 2.18 10.9 10.8 9.9
LeMaitre Vascular Inc $31.84 $37.36 $25.15 -14.8% 26.6% $575.9 $89.2 $18.7 $24.7 $31.8 6.46 30.9 23.3 18.1
Merit Medical Systems Inc $43.20 $42.35 $26.50 2.0% 63.0% $2,423.2 $603.8 $120.8 $124.0 $147.8 4.01 20.1 19.5 16.4

TTM
EBITDA FWD EBITDA
EV /
Sales
EV /
EBITDA
EV /
FWD EBITDA
Ortho, Implants and Prosthetics
Alphatec Holdings Inc $2.66 $2.26 $3.21 17.7% -17.1% $92.9 $120.2 ($3.4) $3.7 $2.7 0.77 nm 25.1 34.4
Exactech Inc $49.45 $32.95 $27.30 50.1% 81.1% $712.7 $257.6 $45.1 $49.6 $52.8 2.77 15.8 14.4 13.5
Globus Medical Inc $41.10 $29.72 $24.81 38.3% 65.7% $3,564.1 $564.0 $211.2 $221.4 $240.2 6.32 16.9 16.1 14.8
Integra LifeSciences Holdings Corp $47.86 $50.48 $42.90 -5.2% 11.6% $4,445.4 $992.1 $247.8 $263.4 $349.1 4.48 17.9 16.9 12.7
NuVasive Inc $58.49 $55.46 $67.36 5.5% -13.2% $3,541.4 $962.1 $240.8 $265.8 $295.8 3.68 14.7 13.3 12.0
Orthofix International NV $54.70 $47.25 $36.18 15.8% 51.2% $943.3 $409.8 $61.1 $75.0 $84.3 2.30 15.4 12.6 11.2
RTI Surgical Inc $4.10 $4.55 $3.25 -9.9% 26.2% $345.0 $272.9 $16.1 $37.5 $41.5 1.26 21.4 9.2 8.3
Wright Medical Group NV $22.20 $25.87 $22.98 -14.2% -3.4% $2,982.8 $690.4 $48.0 $85.0 $119.1 4.32 62.2 35.1 25.0
Zimmer Biomet Holdings Inc $120.67 $116.86 $102.38 3.3% 17.9% $34,050.5 $7,824.1 $2,822.0 $2,847.6 $2,990.1 4.35 12.1 12.0 11.4

TTM
EBITDA FWD EBITDA
EV /
Sales
EV /
EBITDA
EV /
FWD EBITDA
Cosmetics
Cutera Inc $45.35 $41.35 $17.35 9.7% 161.4% $592.4 $151.5 $8.1 $17.1 $21.8 3.91 73.2 34.7 27.2
Dental
Align Technology Inc $222.19 $186.27 $96.13 19.3% 131.1% $17,053.2 $1,473.4 $346.3 $488.4 $628.9 11.57 49.2 34.9 27.1
DENTSPLY SIRONA Inc $65.83 $59.73 $57.41 10.2% 14.7% $16,384.1 $3,745.3 $960.1 $919.0 $982.0 4.37 17.1 17.8 16.7
Pediatric Medical Devices
Natus Medical Inc $38.20 $37.50 $34.80 1.9% 9.8% $1,255.4 $501.0 $68.5 $69.8 $77.8 2.51 18.3 18.0 16.1
Surgery and Life Support Devices
AtriCure Inc $18.24 $22.37 $19.57 -18.5% -6.8% $633.1 $155.1 ($19.8) ($5.2) $2.4 4.08 nm nm 260.8
Intuitive Surgical Inc $364.94 $348.63 $211.39 4.7% 72.6% $38,931.7 $3,128.9 $1,179.0 $1,330.7 $1,528.2 12.44 33.0 29.3 25.5
Misonix Inc $9.45 $10.15 $10.45 -6.9% -9.6% $76.4 $27.3 ($5.5) NA NA 2.80 nm nm nm
NxStage Medical Inc $24.23 $27.60 $26.21 -12.2% -7.6% $1,561.0 $366.4 $19.8 $25.7 $32.5 4.26 78.8 60.9 48.1
Stereotaxis Inc $0.80 $0.82 $0.65 -2.4% 23.1% $19.7 $32.2 ($2.4) NA NA 0.61 nm nm nm
Surmodics Inc $28.00 $31.00 $25.40 -9.7% 10.2% $320.4 $73.1 $10.0 $3.1 $9.3 4.38 32.1 102.4 34.6
Teleflex Inc $248.82 $241.65 $160.10 3.0% 55.4% $12,441.6 $1,868.0 $575.1 $616.3 $716.5 6.66 21.6 20.2 17.4

TTM
EBITDA FWD EBITDA
EV /
Sales
EV /
EBITDA
EV /
FWD EBITDA
General Hospital Devices and Supplies
CONMED Corp $50.97 $52.26 $43.44 -2.5% 17.3% $1,901.8 $796.4 $123.8 $147.0 $153.8 2.39 15.4 12.9 12.4
Digirad Corp $2.51 $3.30 $4.61 -23.7% -45.4% $69.0 $125.5 $11.0 $10.9 $15.3 0.55 6.3 6.3 4.5
Dynatronics Corp $2.88 $2.26 $2.35 27.5% 22.7% $32.7 $35.8 $0.2 NA NA 0.91 203.7 nm nm
FONAR Corp $24.35 $30.50 $19.15 -20.2% 27.2% $153.3 $78.0 $24.9 NA NA 1.96 6.2 nm nm
Intuitive Surgical Inc $364.94 $348.63 $211.39 4.7% 72.6% $38,931.7 $3,128.9 $1,179.0 $1,330.7 $1,528.2 12.44 33.0 29.3 25.5
Masimo Corp $84.80 $86.56 $67.40 -2.0% 25.8% $4,091.8 $694.6 $197.9 $206.0 $227.3 5.89 20.7 19.9 18.0
OPKO Health Inc $4.90 $6.86 $9.30 -28.6% -47.3% $2,788.3 $1,221.7 ($69.3) ($66.8) $5.2 2.28 nm nm 536.2
STERIS PLC $87.47 $88.09 $66.40 -0.7% 31.7% $8,586.9 $2,612.8 $615.5 $642.8 $677.3 3.29 14.0 13.4 12.7
Varian Medical Systems Inc $111.15 $100.06 $79.50 11.1% 39.8% $9,686.8 $2,668.2 $547.1 $582.4 $619.3 3.63 17.7 16.6 15.6
Home Health and Consumer Devices
Invacare Corp $16.84 $15.73 $13.00 7.1% 29.5% $620.2 $966.5 ($14.4) $11.0 $44.5 0.64 nm 56.6 13.9
MSA Safety Inc $77.15 $78.78 $67.70 -2.1% 14.0% $3,316.5 $1,149.5 $216.0 $227.5 $269.8 2.89 15.4 14.6 12.3
ResMed Inc $84.38 $76.35 $60.68 10.5% 39.1% $12,178.1 $2,066.7 $616.9 $683.2 $755.5 5.89 19.7 17.8 16.1

TTM
EBITDA FWD EBITDA
EV /
Sales
EV /
EBITDA
EV /
FWD EBITDA
Other Medical Device
Accuray Inc $4.30 $4.00 $4.60 7.5% -6.5% $426.7 $383.4 $15.5 $26.9 $34.4 1.11 27.6 15.9 12.4
Allied Healthcare Products Inc $2.09 $2.11 $2.00 -0.9% 4.4% $8.4 $33.5 ($0.9) NA NA 0.25 nm nm nm
Cesca Therapeutics Inc $3.00 $3.56 $3.45 -15.7% -13.0% $34.9 $14.5 ($8.2) NA NA 2.40 nm nm nm
Cogentix Medical Inc $3.15 $2.56 $2.01 23.0% 56.7% $166.3 $51.9 $2.6 $2.7 $5.0 3.21 65.2 61.6 33.3
ReShape Lifesciences Inc $1.48 $1.77 $2.00 -16.1% -26.0% $8.7 $0.8 ($23.4) NA NA 11.08 nm nm nm
Escalon Medical Corp $0.21 $0.15 $0.11 39.9% 99.9% $1.6 $11.2 ($0.3) NA NA 0.15 nm nm nm
IRIDEX Corp $7.62 $9.37 $14.06 -18.7% -45.8% $65.5 $46.2 ($8.0) NA NA 1.42 nm nm nm
Micron Solutions Inc $3.50 $3.80 $3.80 -7.9% -7.9% $15.5 $19.6 $0.6 NA NA 0.79 27.4 nm nm
Navidea Biopharmaceuticals Inc $0.36 $0.42 $0.64 -13.6% -43.8% $54.2 $22.0 ($10.4) NA NA 2.47 nm nm nm
Other Diversified Cos with Med-Tech Components
Agilent Technologies Inc $66.97 $63.93 $45.15 4.8% 48.3% $20,894.5 $4,472.0 $1,114.0 $1,205.1 $1,322.8 4.67 18.8 17.3 15.8
Danaher Corp $92.82 $85.65 $77.34 8.4% 20.0% $74,467.5 $18,329.7 $4,166.5 $4,635.4 $5,001.0 4.06 17.9 16.1 14.9
General Electric Co $17.45 $24.01 $30.57 -27.3% -42.9% $231,927.9 $120,468.0 $16,043.0 $16,907.3 $19,555.7 1.93 14.5 13.7 11.9
PerkinElmer Inc $73.06 $68.84 $51.87 6.1% 40.8% $9,863.6 $2,257.0 $467.5 $573.4 $633.1 4.37 21.1 17.2 15.6
Thermo Fisher Scientific Inc $189.88 $189.05 $140.63 0.4% 35.0% $95,814.0 $20,918.0 $5,268.3 $6,028.8 $6,493.9 4.58 18.2 15.9 14.8

Copyright © 2018 Mercer Capital Management, Inc. All rights reserved. It is illegal under Federal law to reproduce this publication or any portion of its contents without the publisher’s permission. Media quotations with source attribution are encouraged.
Reporters requesting additional information or editorial comment should contact Barbara Walters Price at 901.685.2120. Mercer Capital’s Industry Focus is published quarterly and does not constitute legal or financial consulting advice. It is offered as an
information service to our clients and friends. Those interested in specific guidance for legal or accounting matters should seek competent professional advice. Inquiries to discuss specific valuation matters are welcomed. To add your name to our mailing list
to receive this complimentary publication, visit our website at www.mercercapital.com.
BUSINESS VALUATION
FINANCIAL ADVISORY SERVICES
Mercer
Capital
Medical Device
Industry Services
Mercer Capital provides valuation services to start ups, larger public and
private companies, and private equity and venture capital funds.
Mercer Capital’s expertise in the medical device industry spans the following segments:
• Cardiovascular
• Orthopedic Spinal
• Biologics
• Dental
• Diagnostics Equipment
Our services include:
• Purchase price allocations
• Impairment testing
• Portfolio valuation for LP reporting
• Transaction and valuation advisory
• Equity compensation valuation for 409a compliance
Contact a Mercer Capital professional to discuss your needs in confidence.
Contact Us Sujan Rajbhandary, CFA
901.322.9749
sujanr@mercercapital.com
Travis W. Harms, CFA, CPA/ABV
901.322.9760
harmst@mercercapital.com
Atticus Frank
901.322.9754
franka@mercercapital.com
MERCER CAPITAL
Memphis
5100 Poplar Avenue, Suite 2600
Memphis, Tennessee 38137
901.685.2120
Dallas
12201 Merit Drive, Suite 480
Dallas, Texas 75251
214.468.8400
Nashville
102 Woodmont Blvd., Suite 231
Nashville, Tennessee 37205
615.345.0350
www.mercercapital.com

Mercer Capital's Value Focus: Medical Device Industry | Q1 2018 | Featured Article: Five Trends to Watch in the Medical Device Industry

Recommended

Recommended

More Related Content

More from Mercer Capital

More from Mercer Capital (20)

Recently uploaded

Recently uploaded (20)

Mercer Capital's Value Focus: Medical Device Industry | Q1 2018 | Featured Article: Five Trends to Watch in the Medical Device Industry